A proposed COVID-19 vaccine that scatters proteins into the human body to destroy the deadly novel coronavirus in two weeks will be ready for a human trial in a few months, says an article.

A Possible Cure to the COVID-19

This vaccine is the first peer-reviewed antidote to the dangerous novel coronavirus that had caused different parts of the world to implement lockdowns and isolation.

Giving the Shot

The researchers from the University of Pittsburgh stated that the vaccine can be delivered through an injection similar to how the annual flu vaccine is administered.

Testing the Vaccine

The research team from the United States has tested the vaccine on mice. Based on the results of the study, the researchers found out that the vaccine can neutralize the novel coronavirus for 12 months.

It will take 12 to 18 months to make the test publicly available. If the vaccine gets approved, it will be reproduced in thousands of doses every day.

Check these out:

The Pittsburgh Coronavirus Vaccine

An industrial-type of production method had been used to create the Pittsburgh Coronavirus Vaccine or the PittCoVacc. This allows the vaccine to be highly scalable.

This is the first COVID-19 proposed vaccine that has undergone inspection by independent scientists. The findings are included in The Lancet's EBioMedicine journal.

Application for Approval in the US Food and Drug Administration

The researchers of the vaccine are now applying for approval from the United States Food and Drug Administration. They target to start the vaccine's first human trial in a few months.

The University of Pittsburgh's Senior study author Prof. Louis Falo stated that it will take at least a year to reach human testing for the new vaccine. He said that the situation caused by the COVID-19 pandemic is uniquely different. It is difficult to predict the period for the clinical development process, the professor added. However, the recent revision announcement on the study suggests that it may advance faster, says the professor.

Experience from Other Coronaviruses

The Pittsburgh research team was able to take action immediately due to their previous experience with other coronavirus epidemics.

Professor Andrea Gambotto, a senior study author from Pittsburgh stated that they have a clearer view of the direction they need to tackle in combatting the deadly novel coronavirus. She said that the research team had former experience with the 2003 SARS-CoV and the 2014 MERS-CoV. These two viruses are closely related to the SARS-CoV-2 or the novel coronavirus that the world is currently trying to fight.

Gambotto said that, by knowing the similarities of these viruses, the team was able to understand that knowing the virus' so-called 'spike protein' is the key to producing immunity from the deadly virus.

Gambotto also said that this is the main reason why it is important to provide sufficient funding for vaccine research. There is no certainty as to the time another pandemic will hit, she said.